loading
Eledon Pharmaceuticals Inc stock is traded at $3.895, with a volume of 199.18K. It is down -2.50% in the last 24 hours and up +31.31% over the past month. Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$4.00
Open:
$3.92
24h Volume:
199.18K
Relative Volume:
0.58
Market Cap:
$236.66M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-0.6524
EPS:
-5.97
Net Cash Flow:
$-39.53M
1W Performance:
-21.37%
1M Performance:
+31.31%
6M Performance:
+29.14%
1Y Performance:
+207.09%
1-Day Range:
Value
$3.76
$4.07
1-Week Range:
Value
$3.76
$5.00
52-Week Range:
Value
$1.1099
$5.54

Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile

Name
Name
Eledon Pharmaceuticals Inc
Name
Phone
949-238-8090
Name
Address
19800 MACARTHUR BLVD., IRVINE
Name
Employee
20
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ELDN's Discussions on Twitter

Compare ELDN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ELDN 3.90 236.66M 0 -40.33M -39.53M -5.97
VRTX 467.79 119.83B 10.63B -479.80M -1.35B 13.33
REGN 761.02 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.78 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.27 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.65 24.08B 3.30B -501.07M 1.03B 11.54

Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades

Date Action Analyst Rating Change
May-13-22 Resumed Cantor Fitzgerald Overweight
Mar-23-21 Initiated Cantor Fitzgerald Overweight

Eledon Pharmaceuticals Inc Stock (ELDN) Latest News

pulisher
02:54 AM

Research Analysts Set Expectations for ELDN FY2024 Earnings - MarketBeat

02:54 AM
pulisher
Nov 15, 2024

FY2024 Earnings Forecast for ELDN Issued By Lifesci Capital - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Shares in Eledon Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

Institutions along with individual investors who hold considerable shares inEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) come under pressure; lose 16% of holdings value - Simply Wall St

Nov 14, 2024
pulisher
Nov 14, 2024

Hopkins alum leads Eledon Pharmaceuticals in breakthrough diabetes tegoprubart treatment - Johns Hopkins News-Letter

Nov 14, 2024
pulisher
Nov 12, 2024

Eledon Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Eledon Pharma Surges: $85M Offering, Strong Trial Results Drive Q3 Success | ELDN Stock | ELDN Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 08, 2024

Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve

Nov 08, 2024
pulisher
Nov 08, 2024

Midday Stock Roundup: Indie Semiconductor Up 43% - Orange County Business Journal

Nov 08, 2024
pulisher
Nov 06, 2024

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation - The Bakersfield Californian

Nov 06, 2024
pulisher
Nov 06, 2024

Eledon Pharmaceuticals CEO to Present at Guggenheim's First Healthcare Innovation Conference | ELDN Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 05, 2024

RA Capital Management, L.P. Acquires New Stake in Eledon Pharmac - GuruFocus.com

Nov 05, 2024
pulisher
Nov 01, 2024

Biotechnology Value Fund L P's Strategic Acquisition in Eledon P - GuruFocus.com

Nov 01, 2024
pulisher
Oct 31, 2024

ELDN stock touches 52-week high at $4.13 amid robust gains - Investing.com Australia

Oct 31, 2024
pulisher
Oct 30, 2024

ELDN stock touches 52-week high at $4.13 amid robust gains By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow

Oct 30, 2024
pulisher
Oct 30, 2024

Eledon drug helps transplants 'cure' type 1 diabetes - pharmaphorum

Oct 30, 2024
pulisher
Oct 29, 2024

Eledon Pharmaceuticals sets terms for $85 million stock offering By Investing.com - Investing.com South Africa

Oct 29, 2024
pulisher
Oct 29, 2024

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart (ELDN) - Seeking Alpha

Oct 29, 2024
pulisher
Oct 29, 2024

Eledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial Data - MarketWatch

Oct 29, 2024
pulisher
Oct 29, 2024

Promising results for diabetes treatment with new drug By Investing.com - Investing.com Australia

Oct 29, 2024
pulisher
Oct 29, 2024

Eledon Pharmaceuticals sets terms for $85 million stock offering - Investing.com India

Oct 29, 2024
pulisher
Oct 29, 2024

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - The Manila Times

Oct 29, 2024
pulisher
Oct 29, 2024

Promising results for diabetes treatment with new drug - Investing.com India

Oct 29, 2024
pulisher
Oct 29, 2024

Eledon Pharmaceuticals Announces Pricing of $85 Million - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - StockTitan

Oct 29, 2024
pulisher
Oct 26, 2024

Algorae Pharmaceuticals Plans Major Securities Issuance - MSN

Oct 26, 2024
pulisher
Oct 23, 2024

ELDN stock soars to 52-week high, touches $3.35 amid surge - Investing.com

Oct 23, 2024
pulisher
Oct 04, 2024

Financial Analysis: Eledon Pharmaceuticals (NASDAQ:ELDN) & ABVC BioPharma (NASDAQ:ABVC) - Defense World

Oct 04, 2024
pulisher
Oct 03, 2024

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, - openPR

Oct 03, 2024
pulisher
Oct 03, 2024

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight - Barchart

Oct 03, 2024
pulisher
Oct 01, 2024

Eledon Pharmaceuticals completes $4 million equity sale - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

Eledon Pharmaceuticals completes $4 million equity sale By Investing.com - Investing.com South Africa

Oct 01, 2024
pulisher
Oct 01, 2024

Nantahala Capital Management LLC Invests $1.58 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Nantahala Capital Management LLC Acquires New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - MarketBeat

Oct 01, 2024
pulisher
Sep 28, 2024

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Update - MarketBeat

Sep 28, 2024
pulisher
Sep 27, 2024

Midday Stock Roundup: STAAR Surgical CO. Shares Surge 22% - Orange County Business Journal

Sep 27, 2024
pulisher
Sep 20, 2024

Eledon Pharmaceuticals initiates $75 million stock sale agreement By Investing.com - Investing.com Australia

Sep 20, 2024
pulisher
Sep 20, 2024

Eledon Pharmaceuticals initiates $75 million stock sale agreement - Investing.com

Sep 20, 2024
pulisher
Sep 11, 2024

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference - GlobeNewswire

Sep 11, 2024
pulisher
Sep 04, 2024

ELDNEledon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Sep 04, 2024
pulisher
Sep 04, 2024

Eledon Announces Completion of Enrollment in Phase 2 BESTOW - GlobeNewswire

Sep 04, 2024
pulisher
Sep 04, 2024

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients - StockTitan

Sep 04, 2024
pulisher
Sep 02, 2024

Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Declines By 6.8% - MarketBeat

Sep 02, 2024

Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):